Skip to main content

Psoriatic arthritis

      #1456
      💥In a real-world UK PsA cohort, 25% had joint erosion @ diagnosis

      ➡️Mean disease duration 34mo. @ diagnos

      Caoilfhionn Connolly CaoilfhionnMD

      10 months 3 weeks ago
      #1456 💥In a real-world UK PsA cohort, 25% had joint erosion @ diagnosis ➡️Mean disease duration 34mo. @ diagnosis ➡️Mean disability score = mod. to severe 💥Delay in diagnosis=poor outcomes ‼️Are we doing enough to catch PsA early? ? 🔑Earlier detection key #ACR @RheumNow
      #1474
      🔬Severe PsA? Guselkumab (GUS) has promise!

      ➡️In bionaive pts with severe disease activity,
      GUS v. PBO res

      Caoilfhionn Connolly CaoilfhionnMD

      10 months 3 weeks ago
      #1474 🔬Severe PsA? Guselkumab (GUS) has promise! ➡️In bionaive pts with severe disease activity, GUS v. PBO resulted in: 🔴73% improvement in joints 🔴53% lower disease activity 🔴63% better PtGA by 2 years ➡️Rapid results by W2, sustained through W100. #ACR @RheumNow
      #1326
      🔬 Predicting Imminent Inflammatory Arthritis

      ➡️543 anti-CCP+ at-risk (high/low) tracked

      🔑Predictors fo

      Caoilfhionn Connolly CaoilfhionnMD

      10 months 3 weeks ago
      #1326 🔬 Predicting Imminent Inflammatory Arthritis ➡️543 anti-CCP+ at-risk (high/low) tracked 🔑Predictors for IA in high-risk: 🔴EMS≥30min(OR 11) 🔴RF+(OR 6) 🔴US PD(OR 5) 🔴smJTC (OR 5) 🔑Predictors for IA in low risk: 🔴RF+(OR 8) 🔴Anti CCP >3xULN(OR 7) #ACR24 @RheumNow https://t.co/ou9HNcNb8X
      Half of the respondents chose #IL17i for #psoriatic #arthritis #PsA Rx for #Achilles #tendonitis

      Interesting as lots
      O

      Janet Pope Janetbirdope

      10 months 3 weeks ago
      Half of the respondents chose #IL17i for #psoriatic #arthritis #PsA Rx for #Achilles #tendonitis Interesting as lots Of data On #enthesitis wIL23i Likely all Effective #PsA Rx helps #tenosynovitis some have ➡️ data on #efficacy ⬆️ bio rationale #ACR24 @RheumNow @ACRheum https://t.co/wzefjsfdaj
      @DrLauraCoates presented Sex differences in clinical presentations of PsA:

      -Women present >polyarthritis, enthesitis

      Adela Castro AdelaCastro222

      10 months 3 weeks ago
      @DrLauraCoates presented Sex differences in clinical presentations of PsA: -Women present >polyarthritis, enthesitis and worse PROs which translates to ⬆️ DAPSAs in spite of less Rx progression. -Men more oligoarthritis, axial involvement, higher skin disease. #ACR24… https://t.co/iapZF0nZWX https://t.co/jZ79WfxZwh
      🔥Sex matters in PsA

      🔑Differences in :

      ➡️clinical phenotypes
      ➡️radiographic progression
      ➡️disease im

      Caoilfhionn Connolly CaoilfhionnMD

      10 months 3 weeks ago
      🔥Sex matters in PsA 🔑Differences in : ➡️clinical phenotypes ➡️radiographic progression ➡️disease impact ➡️pt perception of disease ➡️response to Rx #ACR24 @RheumNow https://t.co/iOXQmoxgp0
      PsA Ultrasound Updates
      The 3-4-5 rule for positive MRI in axSpA remains.
      The MRI lesion cut-offs demonstrated high performance across different

      Adela Castro AdelaCastro222

      10 months 3 weeks ago
      The 3-4-5 rule for positive MRI in axSpA remains. The MRI lesion cut-offs demonstrated high performance across different features of axSpA (PsO, AAU,IBD). Deep fat and deep sclerosis high specificity for axSpA. #Abst0821 #ACR24 @RheumNow https://t.co/4JM5MHrB8z
      Day 1 Recap at ACR24
      Apremilast Benefits and Risks in PsA
      Factors associated w/ secukinumab response in PsA?

      Analysis of 2.7k pt in EuroSpA

      Associated w/ favorable response

      Brian Jaros, MD Dr_Brian_MD

      10 months 3 weeks ago
      Factors associated w/ secukinumab response in PsA? Analysis of 2.7k pt in EuroSpA Associated w/ favorable response ❗️elevated CRP >10 mg/L ❗️fewer prev tx Associated w/ lower response: ❗️smoking ❗️higher patient global score / HAQ @RheumNow #ACR24 Abstr 2325
      ACR Convergence 2024 opened today with a full slate of presentations, posters and specialty meetings.  The meeting began with a flip: the plenary sessions started at 9AM and the poster session began at 1030 AM. Below are some of the highlights from day one in Washington, DC.
      PsA Potpourri
      RheumNow Day 1 Recap: ACR Convergence 2024 Highlights https://t.co/xjCMpzXhTE

      Dr. John Cush RheumNow

      10 months 3 weeks ago
      RheumNow Day 1 Recap: ACR Convergence 2024 Highlights https://t.co/xjCMpzXhTE
      ×